Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Down 34.1% in October

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the recipient of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 5,460,000 shares, a decrease of 34.1% from the September 30th total of 8,290,000 shares. Based on an average daily volume of 30,150,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 4.0% of the shares of the company are short sold.

Tonix Pharmaceuticals Stock Performance

Tonix Pharmaceuticals stock traded up $0.01 during midday trading on Monday, hitting $0.18. The stock had a trading volume of 16,048,978 shares, compared to its average volume of 10,038,396. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $22.14. The company has a market capitalization of $24.57 million, a PE ratio of 0.00 and a beta of 2.08. The firm’s fifty day moving average is $0.18 and its two-hundred day moving average is $1.88.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Friday, August 16th. The company reported ($19.28) EPS for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The firm had revenue of $2.21 million for the quarter, compared to the consensus estimate of $3.50 million. Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. On average, research analysts forecast that Tonix Pharmaceuticals will post -18 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research report on Monday. They set a “sell” rating for the company. Alliance Global Partners boosted their price objective on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, July 22nd.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC lifted its stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 335,373 shares of the company’s stock after buying an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.